1. Home
  2. TRAX vs SCSC Comparison

TRAX vs SCSC Comparison

Compare TRAX & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

HOLD

Current Price

$43.77

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo ScanSource Inc.

SCSC

ScanSource Inc.

HOLD

Current Price

$60.34

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAX
SCSC
Founded
2025
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2026
1997

Fundamental Metrics

Financial Performance
Metric
TRAX
SCSC
Price
$43.77
$60.34
Analyst Decision
Strong Buy
Hold
Analyst Count
12
4
Target Price
★ $74.17
$64.50
AVG Volume (30 Days)
★ 1.1M
199.8K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.33
EPS
N/A
★ 3.64
Revenue
N/A
★ $3,846,260,000.00
Revenue This Year
N/A
$10.38
Revenue Next Year
N/A
$5.47
P/E Ratio
★ N/A
$16.46
Revenue Growth
N/A
★ 7.79
52 Week Low
$15.69
$33.76
52 Week High
$49.91
$66.78

Technical Indicators

Market Signals
Indicator
TRAX
SCSC
Relative Strength Index (RSI) 65.36 53.94
Support Level $40.72 $58.49
Resistance Level $48.94 $63.10
Average True Range (ATR) 3.24 1.74
MACD 1.47 -0.17
Stochastic Oscillator 92.13 43.66

Price Performance

Historical Comparison
TRAX
SCSC

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

About SCSC ScanSource Inc.

ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.

Share on Social Networks: